2017 Nuclear Medicine & Molecular Imaging News
2017 Alavi-Mandell Award
Dr Ryogo Minamimoto, working with his mentor and senior author Dr Andrei Iagaru, received the 2017 Alavi-Mandell Award for the JNM article "Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer". The two agents target different biological processes and have different distribution patterns in the body. Some patients might benefit from having both scans performed, however. In addition, the agents could be labeled with lutetium-177 for therapeutic uses. The article was published in the April 2016 issue of The Journal of Nuclear Medicine.
Cake presented in celebration of the awards given at the 2017 SNMMI Conference. Congratulations to Drs. David Douglas, George Segall and Guido Davidzon.
SNMMI Emerging Leader Award
Dr. Guido Davidzon won the SNMMI Emerging Leader Award at the 2017 Annual Meeting. This Award recognizes his support of the Sino-American conference and encourages Guido to continue his engagement in leadership activities.
Peter Valk Memorial Award
June 13, 2017
Dr. George Segall received the 2017 Peter Valk Memorial Award from the PET Center of Excellence. This prestigious award recognizes George's significant contributions to the advancement and clinical adoption of PET. Dr. Segall presented "PET/CT and Patient Outcomes" on Tuesday, June 13, 2017 during the SNMMI Annual Meeting in Denver, Colorado.
Ursula Mary Kocemba-Slosky Award
Dr. David Douglas received the 2017 Ursula Mary Kocemba-Slosky, PhD, Professional Relations Fellowship (funded by the ERF). The professional relations fellowship is designed to provide young professionals in nuclear medicine and molecular imaging direct, personal exposure to professional/public relations activities of the SNMMI as they relate to other medical societies and other professional organizations.double or right-click to bring up the editor.
Ambassador of the Month
February 3, 2017
Angie Olmos-Bermudez, winner of the Ambassador of the Month, announced February 2017, has encapulated the performance behind the idea of "People Building Brand". Congratulations Angie! Keep up the wonderful work!
Study "Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors" Published
January 13, 2017
Pamela Kunz, MD, and Erik Mittra, MD, PhD, were among the coauthors on the study "Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors" recently published in the New England Journal of Medicine.
"After many years of hard work by many people in NM as well as in GI oncology, the results of the NETTER-1 trial (Phase 3 study of Lutathera) was just published in the NEJM. This is a great success not only for us, but for all the sites that participated, and for the field of NM. In recent years, this was the first major radioisotope therapy trial that Stanford participated in, and it was a major learning curve for all of us to see how much resources it took to get something like this done. But, hopefully, this is just the start of many future studies and therapies like this, as we continue to develop novel therapies for a variety of indications.
Thanks again to all those who participated in ways small and large to make this a success. This publication belongs to all." - Dr. Erik Mittra